Form 8-K
8-K — Beyond Air, Inc.
Accession: 0001493152-26-014676
Filed: 2026-04-01
Period: 2026-03-26
CIK: 0001641631
SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)
Item: Entry into a Material Definitive Agreement
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — form8-k.htm (Primary)
EX-10.1 (ex10-1.htm)
EX-99.1 (ex99-1.htm)
GRAPHIC (ex99-1_001.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: form8-k.htm · Sequence: 1
false
0001641631
0001641631
2026-03-26
2026-03-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): March 26, 2026
Beyond
Air, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
001-38892
47-3812456
(State
or Other Jurisdiction
of
Incorporation)
(Commission
File
Number)
(I.R.S.
Employer
Identification
No.)
900
Stewart Avenue, Suite 301
Garden
City, NY 11530
(Address
of Principal Executive Offices and Zip Code)
(516)
665-8200
Registrant’s
Telephone Number, Including Area Code
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $.0001 per share
XAIR
The
Nasdaq Stock Market LLC
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry
into a Material Definitive Agreement.
The
description in Item 5.02 below, as it relates to the terms and conditions of the Separation and Release of Claims Agreement with Mr.
Lisi, a copy of which is filed herewith as Exhibit 10.1, is incorporated herein by reference.
Item
5.02. Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Chief
Executive Officer Transition
On
March 26, 2026, Mr. Steven A. Lisi notified the board of directors (“Board”) of Beyond Air, Inc. (“Beyond Air”
or the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Director of
the Board and from all his positions with the Company and its subsidiaries, effective March 27, 2026. Mr. Lisi’s resignation is
not the result of any disagreement with the Company or its Board or any matter relating to the Company’s operations, policies,
or practices.
On
March 27, 2026, The Company executed a Separation and Release of Claims Agreement with Mr. Lisi (“Release Agreement”). The
Release Agreement contains customary protections, including a general release of claims by Mr. Lisi in favor of the Company and certain
other related parties. The Agreement will only go effective after the Revocation Period (which is seven business days from March 27,
2026, and excluding such date) has expired. Pursuant to the terms of the Release Agreement, after the Revocation Period, the Company
shall be obligated to pay Mr. Lisi $650,000 separation pay (representing Mr. Lisi’s base salary as of date of separation) in the
form of compensation continuation over 12 months pursuant to the Company’s regular and customary payroll schedule, less all regular
and customary payroll withholdings. The Company shall also pay Mr. Lisi COBRA premiums for 12 months, as more specifically described
in the Release Agreement. All unvested options and all unvested stock restriction unit awards held by Mr. Lisi as of March 27, 2026,
shall be accelerated and shall immediately vest, and shall continue to remain exercisable for twenty-four (24) months from March 27,
2026.
The
foregoing description of the Release Agreement is not complete and is subject to and qualified in its entirety by reference to the full
text of the Release Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
The
Board, by a unanimous vote, appointed Robert Goodman to serve as CEO of the Company, effective March 27, 2026. Mr. Goodman was appointed
as a director of the Company on June 16, 2025. Mr. Goodman has also served as Chief Commercial Officer since November 2025. He brings
over 25 years of experience in sales strategy, go-to-market execution, strategic partnerships and growth management. He has been instrumental
in shaping the Company’s recent commercial approach and is widely recognized for his ability to expand market penetration and accelerate
product adoption in competitive healthcare sectors. Prior to joining Beyond Air, Mr. Goodman served as Chief Commercial Officer at WEP
Clinical from 2023 to 2024, and ActiGraph from 2022 to 2023, where he led global commercial operations and go to market execution. Earlier
in his career, he spent more than nine years at BioTelemetry, Inc. (acquired by Royal Philips), including as Division President and Business
Head of BioTel Care and Alliance from and Senior Vice President of Global Sales and Marketing at BioTel Research, helping scale multiple
businesses through periods of accelerated growth and strategic transformation. He previously held senior leadership roles at Cardiocore
(acquired by BioTelemetry), Thermo Fisher Scientific, and Pfizer, where he spent 15 years in progressively senior commercial positions.
Mr. Goodman currently serves on the board of Fourth Frontier. He is a retired U.S. Army officer and holds a B.S. degree from Norwich
University.
The
Company has not yet entered into an employment agreement or made other compensation arrangements with Mr. Goodman at this time. As of
the date of filing of this Current Report on Form 8-K, no material changes to Mr. Goodman’s existing compensation arrangements
have been made in connection with his appointment as Chief Executive Officer. The Company intends to promptly begin negotiations with
Mr. Goodman with respect to his employment and will disclose any such agreement or arrangements in a subsequent report with the SEC.
There
are no family relationships between Mr. Goodman and any director or executive officer of the Company, and there are no transactions between
Mr. Goodman and the Company that require disclosure pursuant to Item 404 of Regulation S-K.
Item
7.01. Regulation
FD Disclosure.
On
March 26, 2026, the Company issued a press release announcing the CEO transition and appointment of new CEO described in this Current
Report on Form 8-K. A copy of the press release is furnished herewith as Exhibit 99.1.
The
information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless
of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
10.1
Separation and Release of Claims Agreement by and between the Company and Steven A. Lisi dated March 27, 2026.
99.1
Press Release dated March 26, 2026.
104
Cover
Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BEYOND
AIR, Inc.
Date:
April 1, 2026
By:
/s/
Daniel Moorehead
Name:
Daniel
Moorhead
Title
Chief
Financial Officer
EX-10.1
EX-10.1
Filename: ex10-1.htm · Sequence: 2
Exhibit
10.1
Separation
and Release of Claims Agreement (NY over 40)
This
Separation and Release of Claims Agreement (“Agreement”) is entered into by and between Beyond Air, Inc. (f/k/a AIT
THERAPEUTICS INC. (the “Employer” or “Beyond Air”), on behalf of itself, its parent, subsidiaries,
and other corporate affiliates, and each of their respective present and former employees, officers, directors, owners, shareholders,
and agents, individually and in their official capacities (collectively referred to as the “Employer Group”), and
Steve Lisi (the “Executive”) (the Employer and the Executive are collectively referred to as the “Parties”).
WHEREAS,
the Employer and Executive have previously entered into an employment agreement effective June 30, 2018 (the “Employment Agreement”);
and
WHEREAS,
the Parties now desire to terminate the Executive’s employment with the Employer by mutual agreement in accordance with the terms
and conditions set forth in the Employment Agreement and specifically Section 5.1, and to enter into this Agreement to set forth their
mutual understandings and agreements relating thereto; and
WHEREAS,
the Board of Directors of the Employer has authorized the execution of this Agreement on behalf of the Employer; and
WHEREAS,
the Parties desire to resolve any and all matters between them, including but not limited to those matters arising from the Executive’s
employment and the circumstances of his separation, on the terms set forth herein.
WHEREAS,
All capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement.
NOW
THEREFORE, in consideration of the mutual covenants and promises contained herein and in the Employment Agreement, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
1.
Separation Date.
(a)
The Executive’s last day of employment with the Employer is March 27, 2026 (the “Separation Date”). After the
Separation Date, the Executive will not represent himself as being an employee, officer, director, attorney, agent, or representative
of the Employer Group for any purpose. Except as otherwise set forth in this Agreement, the Separation Date is the employment termination
date for the Executive for all purposes, meaning the Executive is not entitled to any further compensation, monies, or other benefits
from the Employer Group, including coverage under any benefit plans or programs sponsored by the Employer Group, as of the Separation
Date.
(b)
Simultaneously with the execution of this Agreement, the Executive shall execute and deliver to the Corporate Secretary of the Employer
a written resignation from: (i) the Board of Directors of the Employer and all subsidiaries and affiliates on which the Executive serves
as a director, including Beyond Caneer, Ltd. and Neuronos Israel Ltd.; and (ii) all officer positions held with the Employer and any
subsidiary or affiliate, including but not limited to his position as Chief Executive Officer and Chairman of the Board and Chairman
of the Board of each of Beyond Caneer, Ltd. and Neuronos Israel Ltd., effective as of the Separation Date. A form of resignation letter
is attached hereto as Exhibit A. The Executive’s failure to execute and deliver such resignation letter simultaneously herewith
shall constitute a material breach of this Agreement.
2.
Return of Property. The Executive represents and warrants that
the Executive has returned all Employer Group property, including identification cards or badges, access codes or devices, keys, laptops,
computers, telephones, mobile phones, hand-held electronic devices, credit cards, electronically stored documents or files, physical
files, and any other Employer Group property in the Executive’s possession. Executive further acknowledges and agrees that the
Executive no longer has access to and does not claim ownership of any of Employer Group’s cloud storage or social media accounts.
The
Executive further acknowledges that the obligations set forth in Section 7.2 of the Employment Agreement with respect to the return of
property survive the termination of employment and are incorporated herein by reference. The Executive confirms that he has preserved,
and has not deleted, altered, destroyed, concealed, or transferred, any documents, records, or data in his possession, custody, or control
that relate to the matters described in the Company’s investigation conducted prior to the execution of this Agreement.
3.
Executive Representations. The Executive specifically represents,
warrants, and confirms that the Executive:
(a)
has not filed any claims, complaints, or actions of any kind against the Employer Group with any federal, state, or local court or government
or administrative agency or arbitration forum before executing this Agreement. For the avoidance of doubt, this representation does not
include, and the Executive is not required to disclose to the Employer, any claims, complaints, or communications to any Government Agencies
(as defined below);
(b)
has not made any claims or allegations to the Employer Group related to discrimination, sexual harassment, or sexual abuse, and that
none of the payments set forth in this Agreement are related to discrimination, sexual harassment, or sexual abuse;
(c)
has been properly paid for all hours worked for the Employer Group;
(d)
has received all salary, wages, commissions, bonuses, and other compensation due to the Executive through the Separation Date in accordance
with the terms of the Employment Agreement, with the exception of the Executive’s final payroll check for salary and any accrued,
unused vacation, if any, through and including the Separation Date (which will be paid on the next regularly scheduled payroll date for
the pay period including the Separation Date), and the Separation Benefits set forth in Section 4 of this Agreement; and
(e)
has not engaged in any unlawful conduct relating to the business of the Employer Group to the best of the Executive’s knowledge.
If
any of these statements is not true, the Executive cannot sign this Agreement and must notify the Employer immediately in writing of
the statements that are not true. This notice will not automatically disqualify the Executive from receiving the benefits offered in
this Agreement, but will require the Employer’s further review and consideration.
2
4.
Separation Benefits. As consideration for the
Executive’s execution of, non-revocation of, and compliance with this Agreement, including the Executive’s waiver and release
of claims in Section 6,
post-termination obligations set forth in the Employment Agreement,
and other post-termination obligations, and in accordance with Section 5.1 of the Employment Agreement, the Employer agrees to provide
the following benefits to which the Executive is not otherwise entitled, hereinafter referred to as “Separation Benefits”:
(a)
Continued payment of twelve (12) months of Executive’s Base Salary, at the rate of $650,000 per annum (representing the Base Salary
in effect as of the Separation Date), payable in substantially equal installments in accordance with the Employer’s regular payroll
practices, less all relevant taxes and other withholdings, for a period of twelve (12) months starting on the first payroll date following
the Effective Date (defined below) but no later than 60 days after the Separation Date.
(b)
If the Executive is covered under the Beyond Air Plan (“Plan”) when the Executive’s employment with the Employer
ends, and the Executive timely and properly elects COBRA continuation coverage under the Plan, the Executive may be permitted to continue
participation in the Plan under COBRA by continuing to pay premiums to the Employer at the contribution level in effect for active employees
until the earlier of: (i) the expiration of twelve (12) months following the Separation Date; or (ii) the date the Executive becomes
covered under another group health plan. At the end of this period, to the extent the Executive remains eligible for COBRA coverage under
the Plan and the maximum COBRA continuation coverage period has not expired, the Executive is fully responsible to pay any and all premiums
for COBRA coverage through the expiration or termination of the COBRA continuation coverage period; provided, however, that to the extent
this provision of such continuation coverage is not permitted under the terms of the Employer benefit plans or would result in an adverse
tax consequence to the Employer or Executive under the Patient Protection and Affordable Care Act or Section 105(h) of the Internal Revenue
Code of 1986, as amended (the “Code”), the Employer may alternatively provide Executive with a cash payment in an
amount equal to the applicable COBRA premium that Executive would otherwise be required to pay to obtain COBRA continuation coverage
for such benefits for such period (minus the cost of such benefits to the same extent that active employees of the Employer are required
to pay for such benefits from time to time).
Notwithstanding
the foregoing, no payment shall be made or begin before the Effective Date of this Agreement.
(c)
All options and all restricted stock unit awards held by the Executive that are vested as of the Separation Date shall remain exercisable
for a period of twenty-four (24) months following the Separation Date, after which they shall expire unexercised.
3
(d)
All unvested options and all unvested stock restriction unit awards held by the Executive as of the Separation Date shall be accelerated
and shall vest as of the Separation Date, and shall be exercisable for a period of twenty-four (24) months following the Separation Date,
after which they shall expire unexercised.
(e)
Executive agrees to direct all requests for references to Employer’s Human Resources Department. In response to a request for a
reference, Employer Group shall provide only Executive’s dates of employment and job title.
(f)
The Executive acknowledges that any change in his beneficial ownership of Company securities resulting from the treatment of equity awards
under this Section 4(e) may require the filing of a Form 4 under Section 16 of the Securities Exchange Act of 1934 within two (2) business
days of the relevant transaction. The Executive agrees to cooperate with the Company and timely execute any required Section 16 filings;
and
(g)
Sections 4(b) and 4(c) supersede and control over any inconsistent term in the applicable award agreements with respect to the treatment
of the Executive’s equity upon the mutual termination of his employment, but shall not affect the continued applicability of all
other terms of such award agreements, including the prohibition on insider trading and the Company’s right to recover equity-related
compensation under its clawback policy.
(h)
Notwithstanding any other provision of this Agreement, the Executive acknowledges and agrees that to the extent applicable:
(i)
Any incentive-based compensation received by the Executive that is subject to the Employer’s Compensation Recovery Policy (the
“Clawback Policy”), as adopted pursuant to SEC Rule 10D-1 and applicable exchange listing standards, remains subject
to recovery by the Employer pursuant to the Clawback Policy, regardless of the execution of this Agreement;
(ii)
Nothing in this Agreement constitutes a waiver of the Employer’s rights under the Clawback Policy, and the Employer’s obligations
to recover erroneously awarded compensation under the Clawback Policy cannot be waived by contract;
(iii)
The Employer shall not indemnify the Executive against the loss of any compensation that is subject to recovery under the Clawback Policy;
and
(iv)
The Executive agrees to cooperate with the Employer in connection with any audit, investigation, or proceeding relating to the Clawback
Policy, including by providing such documentation and information as the Employer may reasonably request.
The
Executive further understands and acknowledges that the Executive is not entitled to any additional payment or consideration not specifically
referenced in this Agreement. Nothing in this Agreement shall be deemed or construed as an express or implied policy or practice of the
Employer Group to provide these or other benefits to any individuals other than the Executive.
4
5.
Public Disclosure. The Parties acknowledge that the Employer is required to file a Current Report on Form 8-K with the Securities
and Exchange Commission within four (4) business days of the Separation Date disclosing the Executive’s departure as principal
executive officer and Chairman of the Board of Directors pursuant to Item 5.02 of Form 8-K. The Parties agree that the Form 8-K shall
describe the separation as a mutual agreement between the Parties and shall not characterize the separation in a manner inconsistent
with Section 5.1 of the Employment Agreement. The Executive agrees not to make any public statement, filing, or communication that is
inconsistent with the characterization of his departure in the Form 8-K, subject to the Executive’s rights to communicate truthfully
with any governmental agency. Nothing in this Section prevents the Employer from making all disclosures required by applicable securities
laws and regulations, including but not limited to disclosures regarding executive compensation under Regulation S-K, Item 402.
6.
Release.
(a)
Executive’s General Release and Waiver of Claims
In
exchange for the consideration provided in this Agreement, the Executive and the Executive’s heirs, executors, representatives,
administrators, agents, insurers, and assigns (collectively, the “Releasors”) irrevocably and unconditionally fully
and forever waive, release, and discharge the Employer Group, including each member of the Employer Group’s parents, subsidiaries,
affiliates, predecessors, successors, and assigns, and each of its and their respective officers, directors, employees, shareholders,
trustees, and partners, in their corporate and individual capacities (collectively, the “Released Parties”), from
any and all claims, demands, actions, causes of actions, judgments, rights, fees, damages, debts, obligations, liabilities, and expenses
(inclusive of attorneys’ fees) of any kind whatsoever, whether known or unknown (collectively, “Claims”), that
Releasors may have or have ever had against the Released Parties, or any of them, arising out of, or in any way related to the Executive’s
hire, benefits, employment, termination, or separation from employment with the Employer Group by reason of any actual or alleged act,
omission, transaction, practice, conduct, occurrence, or other matter from the beginning of time up to and including the date of the
Executive’s execution of this Agreement, including, but not limited to:
(i)
any and all claims under Title VII of the Civil Rights Act of 1964 (Title VII), the Americans with Disabilities Act (ADA), the Family
and Medical Leave Act (FMLA) (regarding existing but not prospective claims), the Fair Labor Standards Act (FLSA), the Equal Pay Act,
the Employee Retirement Income Security Act (ERISA) (regarding unvested benefits), the Civil Rights Act of 1991, Section 1981 of U.S.C.
Title 42, the Fair Credit Reporting Act (FCRA), the Worker Adjustment and Retraining Notification (WARN) Act, the National Labor Relations
Act (NLRA), the Age Discrimination in Employment Act (ADEA), the Uniform Services Employment and Reemployment Rights Act (USERRA), the
Genetic Information Nondiscrimination Act (GINA), the Immigration Reform and Control Act (IRCA), the New York State Human Rights Law
(NYSHRL), the New York Labor Law (NYLL) (including but not limited to the Retaliatory Action by Employers Law, the New York State Worker
Adjustment and Retraining Notification Act, all provisions prohibiting discrimination and retaliation, and all provisions regulating
wage and hour law and paid sick leave requirements), the New York Civil Rights Law, Section 125 of the New York Workers’ Compensation
Law, Article 23-A of the New York Correction Law, the New York City Human Rights Law (NYCHRL), as amended by the New York City Pregnant
Workers Fairness Act, and the New York City Paid Safe and Sick Leave Law, all including any amendments and their respective implementing
regulations, and any other federal, state, local, or foreign law (statutory, regulatory, or otherwise) that may be legally waived and
released; however, the identification of specific statutes is for purposes of example only, and the omission of any specific statute
or law shall not limit the scope of this general release in any manner;
5
(ii)
any and all claims for compensation of any type whatsoever, including but not limited to claims for salary, wages, bonuses, commissions,
incentive compensation, vacation, and severance that may be legally waived and released; for clarity, this Section 4(a)(ii) does not
include the above defined Separation Benefits;
(iii)
any and all claims arising under tort, contract, and quasi-contract law, including but not limited to claims of breach of an express
or implied contract, tortious interference with contract or prospective business advantage, breach of the covenant of good faith and
fair dealing, promissory estoppel, detrimental reliance, invasion of privacy, nonphysical injury, personal injury or sickness or any
other harm, wrongful or retaliatory discharge, fraud, defamation, slander, libel, false imprisonment, and negligent or intentional infliction
of emotional distress; and
(iv)
any and all claims for monetary or equitable relief, including but not limited to attorneys’ fees, back pay, front pay, reinstatement,
experts’ fees, medical fees or expenses, costs and disbursements, punitive damages, liquidated damages, and penalties.
However,
this general release and waiver of claims excludes, and the Executive does not waive, release, or discharge: (A) any right to file an
administrative charge or complaint with, or testify, assist, or participate in an investigation, hearing, or proceeding conducted by,
the Equal Employment Opportunity Commission or other similar federal or state administrative agencies, although the Executive waives
any right to monetary relief related to any filed charge or administrative complaint; (B) claims that cannot be waived by law; (C) any
right to file an unfair labor practice charge under the National Labor Relations Act; (D) protections against retaliation under the Taxpayer
First Act (26 U.S.C. § 2623(d)); (E) any rights to vested benefits, such as pension or retirement benefits, the rights to which
are governed by the terms of the applicable plan documents and award agreements, (F) Employer’s breach of any terms and conditions
of the Agreement, (G) events, acts, or omissions taking place after the Parties’ execution of the Agreement, (H) the right to communicate
directly with, provide information to, or receive financial awards from the Securities and Exchange Commission pursuant to Section 21F
of the Securities Exchange Act of 1934, as amended, and SEC Rule 21F-17 thereunder; no provision of this Agreement shall be construed
to prevent, impede, or restrict such communications, and the Employer shall not enforce or threaten to enforce any provision of this
Agreement to prevent the Executive from communicating with the SEC regarding any matter that may constitute a possible violation of the
federal securities laws; (I) rights under the anti-retaliation provisions of the Sarbanes-Oxley Act of 2002, Section 806 (18 U.S.C. §
1514A), and the Dodd-Frank Wall Street Reform and Consumer Protection Act, Section 922 (15 U.S.C. § 78u-6); (J) rights under New
York Labor Law § 740 (private-sector whistleblower protection) with respect to disclosures of information to a governmental body,
and the anti-retaliation protections thereunder; and (K) rights to indemnification and continued D&O insurance coverage as set forth
in Section 21 of this Agreement and as otherwise provided by law, the Employer’s certificate of incorporation and bylaws, and any
separate indemnification agreement between the Executive and the Employer, all of which survive the termination of employment.
6
(b)
Specific Release of ADEA Claims
In
further consideration of the payments and benefits provided to the Executive in this Agreement, the Releasors hereby irrevocably and
unconditionally fully and forever waive, release, and discharge the Released Parties from any and all Claims, whether known or unknown,
from the beginning of time through the date of the Executive’s execution of this Agreement, arising under the Age Discrimination
in Employment Act (ADEA), as amended, and its implementing regulations. By signing this Agreement, the Executive hereby acknowledges
and confirms that:
(i)
the Executive has read this Agreement in its entirety and understands all of its terms;
(ii)
by this Agreement, the Executive has been advised in writing to consult with an attorney of the Executive’s choosing and has consulted
with such counsel as the Executive believed was necessary before signing this Agreement.
(iii)
the Executive knowingly, freely, and voluntarily agrees to all of the terms and conditions set out in this Agreement including, without
limitation, the waiver, release, and covenants contained in it;
(iv)
the Executive is signing this Agreement, including the waiver and release, in exchange for good and valuable consideration in addition
to anything of value to which the Executive is otherwise entitled.
(v)
the Executive was given at least twenty-one (21) days to consider the terms of this Agreement and consult with an attorney of the Executive’s
choice, although the Executive may sign it sooner if desired and changes to this Agreement, whether material or immaterial, do not restart
the running of the 21-day period (“Review Period”);
7
(vi)
the Executive understands that the Executive has seven (7) days after signing this Agreement to revoke the release in this paragraph
by delivering notice of revocation to Adam Newman at the Employer, by personal delivery or by email at anewman@beyondair.net before the
end of this seven-day period; and
(vii)
the Executive understands that the release contained in this paragraph does not apply to rights and claims that may arise after the Executive
signs this Agreement.
(c)
Employer Release of Executive.
In
exchange for the Releasors’ waiver and release of claims against the Released Parties, and non-revocation of any portion of that
release, the Employer expressly waives and releases any and all claims against the Executive that may be waived and released by law.
7.
Effective Date. This Agreement is effective seven (7) calendar days after Executive executes this Agreement provided Executive
does not revoke the Agreement pursuant to Section 5(b)(vi) and Employer executes this Agreement prior to the end of the revocation period.
Any revocation shall be in writing and emailed to Adam Newman at anewman@beyondair.net.
This
Agreement shall not become effective, therefore, and none of the payments or benefits set forth in this Agreement shall become due until
(a) Executive has timely executed this Agreement, (b) the seven-day revocation period has expired without revocation being exercised,
and (c) Executive has satisfied each of his obligations in this Agreement (the “Effective Date”). A signed copy of
the Agreement shall be returned to the email address above.
8.
Executive Non-Disparagement. The Executive agrees and covenants
that the Executive shall not, directly or indirectly, at any time, make, publish, or communicate in any medium or forum (including verbal,
written, or electronic communications, and social or digital platforms such as LinkedIn, Facebook, X/Twitter, Glassdoor, or other review
sites) any statements, comments, postings, or communications that are defamatory, knowingly false, disparaging, or reasonably likely
to damage the reputation, business, or goodwill of the Employer Group, its subsidiaries, affiliates, shareholders, investors, officers,
directors, employees, agents, products, or services.
This
restriction includes statements made anonymously or pseudonymously on internet or electronic platforms, or through third parties acting
on the Executive’s behalf. The Executive further agrees not to counsel, assist, or encourage any other person or entity to make
such statements.
8
Nothing
in this Section shall restrict or impede the Executive from: (i) exercising rights that cannot be waived by law, including under the
National Labor Relations Act, whistleblower provisions, or applicable securities laws; (ii) making truthful statements required by law,
subpoena, court order, or government agency directive; (iii) cooperating with or participating in any investigation or proceeding by
the Equal Employment Opportunity Commission (“EEOC”) or other government enforcement agency; (iv) raising truthful complaints
or claims of sexual harassment, sexual assault, or other unlawful workplace conduct; (v) communicating directly with the Securities and
Exchange Commission, the Financial Industry Regulatory Authority, or any other federal or state governmental or regulatory authority,
regarding any matter that may constitute a possible violation of the federal or state securities laws, including pursuant to SEC Rule
21F-17; or (vi) providing truthful testimony in any legal, administrative, or arbitration proceeding.
The
Executive shall, unless prohibited by law, provide written notice to the Employer’s General Counsel of any legal requirement to
make a disclosure described in this paragraph within three (3) business days of receiving such requirement.
If
the Executive breaches this clause, the Employer may seek equitable relief (including injunctive relief) and recovery of any damages
caused by such breach.
9.
Employer Non-Disparagement. The Employer agrees and covenants
that the Employer shall not, directly or indirectly, at any time, make, publish, or communicate in any medium or forum (including verbal,
written, or electronic communications, and social or digital platforms such as LinkedIn, Facebook, X/Twitter, Glassdoor, or other review
sites) any statements, comments, postings, or communications that are defamatory, knowingly false, disparaging, or reasonably likely
to damage the reputation, business, or goodwill of the Executive.
This
restriction includes statements made anonymously or pseudonymously on internet or electronic platforms, or through third parties acting
on the Employer’s behalf. The Employer further agrees not to counsel, assist, or encourage any other person or entity to make such
statements.
The
Employer shall, unless prohibited by law, provide written notice to the Executive of any legal requirement to make a disclosure described
in this paragraph within three (3) business days of receiving such requirement.
If
the Employer breaches this clause, the Executive may seek equitable relief (including injunctive relief) and recovery of any damages
caused by such breach.
10.
Remedies. In the event of a breach or threatened breach by
either Party of any provision of this Agreement, each Party hereby consents and agrees that money damages would not afford an adequate
remedy and that the non-breaching Party shall be entitled to seek a temporary or permanent injunction or other equitable relief against
such breach or threatened breach from a court of competent jurisdiction, without the necessity of showing any actual damages, and without
the necessity of posting any bond or other security. Any equitable relief shall be in addition to, not instead of, legal remedies, monetary
damages, or other available relief. In any action, proceeding, or arbitration arising out of or relating to this Agreement, the prevailing
Party shall be entitled to recover from the non-prevailing Party its reasonable attorneys’ fees, costs, and expenses incurred in
connection with such action, proceeding, or arbitration, including any appeals therefrom.
9
If
the Executive fails to comply with any of the terms of this Agreement or post-employment obligations contained in it, the Employer may,
in addition to any other available remedies, reclaim any amounts paid to the Executive under the provisions of this Agreement and terminate
any benefits or payments that are later due under this Agreement, without waiving the releases provided in it; provided, however, that
this clawback right shall not be exercised in a manner that penalizes the Executive for exercising his rights under the ADEA, the EEOC
charge-filing process, or Section 21F of the Securities Exchange Act of 1934.
The
Parties mutually agree that this Agreement can be specifically enforced in court and can be cited as evidence in legal proceedings alleging
breach of the Agreement.
11.
Successors and Assigns.
(a)
Assignment by the Employer Group
The
Employer Group may freely assign this Agreement at any time. This Agreement shall inure to the benefit of the Employer Group and its
successors and assigns.
(b)
No Assignment by the Executive
The
Executive may not assign this Agreement in whole or in part. Any purported assignment by the Executive shall be null and void from the
initial date of the purported assignment. Notwithstanding the foregoing, in the event of the Executive’s death, all benefits accrued
or payable under this Agreement shall inure to the benefit of the Executive’s estate.
12.
Governing Law and Dispute Resolution.
(a)
Governing Law. This Agreement and all matters arising out of or relating to this Agreement and the Executive’s employment
or termination of employment with Beyond Air, whether sounding in contract, tort, or statute, for all purposes shall be governed by and
construed in accordance with the laws of New York (including its statutes of limitations) without regard to any conflicts of laws principles
that would require the laws of any other jurisdiction to apply.
(b)
Mandatory Arbitration. Except as provided in Section 12(c) below, any and all disputes, claims, or controversies between the Parties
arising out of or relating to this Agreement, the Employment Agreement, the Executive’s employment with the Employer Group, or
the termination of that employment, (including any dispute about the validity, enforceability, scope, or breach of this Agreement or
the Employment Agreement) shall be resolved by final and binding arbitration administered by the American Arbitration Association (“AAA”)
in accordance with the AAA’s National Rules for the Resolution of Employment Disputes then in effect (the “AAA Rules”),
which are incorporated herein by reference. The arbitration shall be conducted before a single neutral arbitrator unless the AAA Rules
require a panel. The arbitration shall take place in New York County, New York. The arbitrator shall apply New York substantive law and
the Federal Rules of Evidence. The arbitrator shall have authority to award any remedy or relief that a court of competent jurisdiction
could order or grant, including, without limitation, the specific performance of any obligation under this Agreement or the Employment
Agreement, and the issuance of permanent injunctive relief. The arbitrator’s award shall be in writing, shall state the reasons
for the award, and shall be final and binding on the Parties. Judgment upon the award may be entered in any court of competent jurisdiction.
The costs and fees of the arbitrator shall be shared equally by the Parties, unless the arbitrator determines otherwise. Each Party shall
bear its own attorneys’ fees and costs in connection with the arbitration, subject to the Parties’ rights under Section 21
of this Agreement.
10
(c)
The Parties acknowledge and agree that this Section 12(b) is intended to be consistent with, and an extension of, the arbitration obligations
set forth in Section 11 of the Employment Agreement, and that all disputes arising under both this Agreement and the Employment Agreement
shall be resolved in a single arbitration proceeding to the extent practicable.
(d)
Exception for Equitable Relief. Notwithstanding Section 12(b), either Party may seek temporary or preliminary injunctive or other
emergency equitable relief from a court of competent jurisdiction — without first initiating or completing arbitration —
where necessary to prevent irreparable harm pending the arbitration of the underlying dispute. The Parties hereby irrevocably submit
to the exclusive jurisdiction of the state and federal courts located in New York County, New York for the limited purpose of any such
emergency equitable proceeding. The seeking of such interim relief shall not be deemed a waiver of the right to arbitrate, and the court
proceeding shall be stayed as to the merits of any dispute pending completion of the arbitration.
(e)
ADEA / OWBPA Arbitration Carve-Out. Nothing in this Section 12 shall be construed to limit the Executive’s right to: (i)
file a charge or complaint with the Equal Employment Opportunity Commission (EEOC) or any similar state or local administrative agency;
(ii) participate in any EEOC or governmental agency investigation or proceeding; (iii) challenge the validity of the ADEA waiver contained
in Section 5(b) of this Agreement; or (iv) file a lawsuit in court solely to challenge the enforceability of the ADEA waiver under the
Older Workers Benefit Protection Act. An individual alleging that a waiver agreement was not knowing and voluntary under the ADEA is
not required to tender back the consideration given for that agreement before filing either a lawsuit or a charge of discrimination with
the EEOC or any state or local fair employment practices agency. The arbitration obligation in Section 12(b) shall not be enforced against
the Executive with respect to any claim challenging the validity of the ADEA waiver.
(f)
Class Action and Collective Action Waiver. The Executive and the Employer each agree that any arbitration shall be conducted solely
on an individual basis and not as a class action, collective action, or representative action. Neither Party shall seek to have any dispute
heard as a class action, collective action, or representative action, and the arbitrator shall have no authority to consolidate more
than one person’s claims or to otherwise preside over any form of a class, collective, or representative proceeding.
(g)
Survival. This Section 12 shall survive the termination or expiration of this Agreement.
11
13.
Entire Agreement. Unless specifically provided herein, this
Agreement contains all of the understandings and representations between Employer Group and Executive relating to the subject matter
hereof and supersedes all prior and contemporaneous understandings, discussions, agreements, representations, and warranties, both written
and oral, regarding such subject matter; provided, however, that nothing in this Agreement modifies, supersedes, voids, or otherwise
alters the Executive’s ongoing obligations under the Employment Agreement, including but not limited to the restrictive covenants
contained therein, which shall remain in full force and effect.
In
the event of any inconsistency between this Agreement and any other agreement between the Executive and the Employer Group, the statements
in this Agreement shall control with respect to the subject matter of this Agreement (i.e., the terms and conditions of the Executive’s
separation), and the Employment Agreement shall control with respect to all surviving post-termination obligations, including but not
limited to the confidentiality, non-solicitation, non-competition, and cooperation obligations set forth in Sections 7 through 10.3 of
the Employment Agreement.
14.
Modification and Waiver. No provision of this
Agreement may be amended or modified unless the amendment or modification is agreed to in writing and signed by the Executive and by
an authorized representative of the Employer. No waiver by either Party of any breach by the other party of any condition or provision
of this Agreement to be performed by the other Party shall be deemed a waiver of any similar or dissimilar provision or condition at
the same or any prior or subsequent time, nor shall the failure of or delay by either Party in exercising any right, power, or privilege
under this Agreement operate as a waiver thereof to preclude any other or further exercise thereof or the exercise of any other such
right, power, or privilege.
15.
Severability. If any provision of this Agreement
is found by a court of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, or enforceable only if modified,
such finding shall not affect the validity of the remainder of this Agreement, which shall remain in full force and effect and continue
to be binding on the Parties.
The
Parties further agree that any such court is expressly authorized to modify any such invalid, illegal, or unenforceable provision of
this Agreement instead of severing the provision from this Agreement in its entirety, whether by rewriting, deleting, or adding to the
offending provision, or by making such other modifications as it deems necessary to carry out the intent and agreement of the Parties
as embodied in this Agreement to the maximum extent permitted by law. Any such modification shall become a part of and treated as though
originally set forth in this Agreement. If such provision or provisions are not modified, this Agreement shall be construed as if such
invalid, illegal, or unenforceable provisions had not been set forth in it. The Parties expressly agree that this Agreement as so modified
by the court shall be binding on and enforceable against each of them.
16.
Interpretation. Captions and headings of the
sections and paragraphs of this Agreement are intended solely for convenience, and no provision of this Agreement is to be construed
by reference to the caption or heading of any section or paragraph. Moreover, this Agreement shall not be construed against either Party
as the author or drafter of the Agreement.
12
17.
Counterparts. The Parties may execute this Agreement
in counterparts, each of which shall be deemed an original, and all of which taken together shall constitute one and the same instrument.
Delivery of an executed counterpart’s signature page of this Agreement by email in portable document format (pdf), or by any other
electronic means intended to preserve the original graphic and pictorial appearance of a document has the same effect as delivery of
an executed original of this Agreement.
18.
No Admission of Liability. Nothing in this Agreement shall
be construed as an admission by the Executive or the Employer Group of any wrongdoing, liability, or noncompliance with any federal,
state, city, or local rule, ordinance, statute, common law, or other legal obligation.
19.
Notices. All notices under this Agreement must be given in
writing by receipted email at the addresses indicated in this Agreement or any other address designated in writing by either Party. When
providing written notice to Employer Group, a copy must be provided to Employer’s General Counsel at the address below.
Notice
to Employer Group:
Adam Newman
anewman@beyondair.net
Notice to
the Executive:
Steve Lisi
9
McGann Drive
Rockville Centre, New York
snllisi@yahoo.com
With copy to: [Executive’s Counsel NAME, FIRM, EMAIL]
20.
Tolling. If the Executive violates any of the
post-termination obligations referenced in this Agreement, the obligation at issue will run from the first date on which the Executive
ceases to be in violation of such obligation.
21.
Director and Officer Indemnification and Insurance.
(a)
Notwithstanding any other provision of this Agreement, the Employer’s obligations to indemnify the Executive for acts and omissions
during his tenure as CEO and Chairman of the Board of Directors, as provided by: (a) the Employer’s Certificate of Incorporation
and Bylaws; (b) the Delaware General Corporation Law; (c) any separate indemnification agreement between the Executive and the Employer;
and (d) applicable law, shall survive the termination of the Executive’s employment and shall not be affected by this Agreement.
Without limiting the foregoing, the Employer shall continue to advance or pay, as incurred, all reasonable attorneys’ fees and
other defense costs incurred by the Executive in connection with any current or future claim, action, suit, or proceeding arising out
of or relating to acts or omissions during the Executive’s tenure as CEO or Chairman of the Board of Directors, to the fullest
extent permitted by applicable law.
13
(b)
The Employer shall maintain a directors and officers liability insurance policy providing coverage to the Executive for acts and omissions
during his tenure for not less than six (6) years following the Separation Date, at coverage levels not less than those maintained immediately
prior to the Separation Date (“Tail
Coverage”). If the Employer is unable to maintain Tail Coverage on commercially reasonable
terms, the Employer shall purchase the maximum amount of Tail Coverage available on commercially reasonable terms.
22.
Post-Termination Cooperation. For a period of three (3) years following the Separation Date, the Executive agrees to make
himself reasonably available and to cooperate fully with the Employer, its Board of Directors, outside counsel, auditors, and authorized
representatives in connection with:
(a)
any governmental, regulatory, or securities law investigation or proceeding, including but not limited to any inquiry by the Securities
and Exchange Commission, the Financial Industry Regulatory Authority, or any other federal or state agency;
(b)
any review of the Employer’s financial statements, including any restatement process, relating to periods during which the Executive
served as CEO;
(c)
any litigation, arbitration, or other legal proceeding in which the Employer is a party and which relates to events occurring during
the Executive’s tenure; and
(d)
the transition of his duties to his successor, including making himself available for reasonable questions and briefings.
The
Employer shall: (i) reimburse the Executive for all reasonable out-of-pocket expenses incurred in connection with such cooperation; (ii)
schedule cooperation activities at times reasonably convenient to the Executive; and (iii) provide reasonable advance notice of cooperation
requests. Nothing in this Section requires the Executive to waive any applicable privilege, including attorney-client privilege.
23.
Attorneys’ Fees and Costs. In the event
that either Party breaches any term of this Agreement or the post-termination obligations referenced and/or set forth herein, and a legal
action (including arbitration) is commenced to enforce, interpret, or defend the Agreement or any provision thereof, the prevailing Party
shall be entitled, to the extent permitted by applicable law, to recover from the non-prevailing Party all reasonable attorneys’
fees and costs incurred in connection with such enforcement, interpretation, defense, or demonstration of breach, as well as in any appellate
or post-judgment proceeding related thereto. For purposes of this provision, the “Prevailing Party” shall mean the Party
that substantially obtains the relief sought, whether by settlement, judgment, or award.
24.
Section 409A. This Agreement and the payments
hereunder are intended to comply with or satisfy an exemption from Code Section 409A o, and shall be construed and administered in accordance
with such intent. Notwithstanding any other provision of this Agreement, payments provided under this Agreement may only be made upon
an event and in a manner that complies with Section 409A or an applicable exemption. Any payments under this Agreement that may be excluded
from Section 409A either as separation pay due to an involuntary separation from service, as a short-term deferral, or as a settlement
payment pursuant to a bona fide legal dispute shall be excluded from Section 409A to the maximum extent possible. For purposes of Section
409A, any installment payments provided under this Agreement shall each be treated as a separate payment. To the extent required under
Section 409A, any payments to be made under this Agreement in connection with a termination of employment shall only be made if such
termination constitutes a “separation from service” under Section 409A. Notwithstanding the foregoing, Employer Group makes
no representations that the payments and benefits provided under this Agreement comply with Section 409A and in no event shall Employer
Group be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by Executive on account
of non-compliance with Section 409A.
25.
Notice of Post-Termination Obligations. When
the Executive’s employment with the Employer terminates, the Executive agrees to notify any subsequent employer of the restrictive
covenants referenced in this Agreement. In addition, the Executive authorizes the Employer Group to provide a copy of the restrictive
covenants contained in the Employment Agreement to third parties, including but not limited to, the Executive’s subsequent, anticipated,
or possible future employer.
26.
Acknowledgment of Full Understanding. THE EXECUTIVE
ACKNOWLEDGES AND AGREES THAT THE EXECUTIVE HAS FULLY READ, UNDERSTANDS, AND VOLUNTARILY ENTERS INTO THIS AGREEMENT. THE EXECUTIVE ACKNOWLEDGES
AND AGREES THAT THE EXECUTIVE HAS HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF THE EXECUTIVE’S CHOICE BEFORE
SIGNING THIS AGREEMENT. THE EXECUTIVE FURTHER ACKNOWLEDGES THAT THE EXECUTIVE’S SIGNATURE BELOW IS AN AGREEMENT TO RELEASE EMPLOYER
GROUP FROM ANY AND ALL CLAIMS THAT CAN BE RELEASED AS A MATTER OF LAW.
[signature
page follows]
14
IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date set forth below.
EXECUTIVE
Beyond
Air, Inc. (f/k/a AIT Therapeutics Inc.)
Signature:
/s/
Steve Lisi
By:
/s/
Robert F. Carey
Name:
Steve
Lisi
Name:
Robert
F. Carey
Title:
Chief
Executive Officer
Title:
Chairman
of the Board
Date:
Date:
15
EX-99.1
EX-99.1
Filename: ex99-1.htm · Sequence: 3
Exhibit
99.1
Beyond
Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO
New
Leadership to Accelerate Market Adoption and Scale Commercial Growth
GARDEN
CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”),
a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives
of patients, today announced that Steve Lisi has resigned as Chief Executive Officer and stepped down from the Board of Directors, effective
March 27, 2026, to pursue other opportunities. The Board of Directors has appointed Robert Goodman, the Company’s current Chief
Commercial Officer and Director, as Chief Executive Officer, effective today.
For
the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of the Company’s LungFit PH. Under his leadership,
the Company successfully brought this revolutionary technology to market and established a strong foundation for the LungFit franchise
to accelerate Beyond Air’s growth.
“On
behalf of the entire Board, I want to thank Steve for his many years of dedicated service and visionary leadership,” said Robert
F. Carey, Chairman of the Board. “His contributions were critical in developing the LungFit system and positioning the Company
for its next phase. As we focus on accelerating widespread market adoption of LungFit PH and scaling our commercial operations, the Board
is confident that Bob Goodman’s proven commercial and operational expertise in both the U.S. and international markets makes him
the ideal leader to drive broader customer deployment and unlock Beyond Air’s true potential.”
“I
am deeply grateful for the opportunity to have led Beyond Air through its formative growth years,” said Steve Lisi. “We have
built an exceptional platform with tremendous upside. I have complete confidence in the Beyond Air team to scale the business to new
heights.”
“I
am honored by the Board’s trust and excited to lead Beyond Air into this next chapter,” said Robert Goodman, incoming Chief
Executive Officer. “Our technology delivers clear value, and we have a significant opportunity to expand adoption in the U.S. and
international inhaled nitric oxide markets. I am fully committed to sharpening our commercial execution, strengthening customer partnerships,
scaling the Company to achieve its substantial long-term potential and delivering enhanced value for shareholders.”
Mr.
Goodman is a seasoned healthcare executive and board director with a distinguished track record of leadership across the medical technology
and pharmaceutical industries. He joined the Board of Beyond Air in June 2025 and served as Chief Commercial Officer from November 2025
to March 2026 where he led a rapid transformation of the business strategy, grounded in technology, process and people, positioning the
business for scalable and sustainable growth. He brings decades of experience guiding companies through rapid growth and global expansion
consistently exceeding stakeholder expectations including multiple successful exits.
Mr.
Goodman has held key leadership roles at a range of high-performing organizations, including BioTelemetry, Philips Healthcare, Cardiocore,
Thermo Fisher Scientific, and Pfizer. Spanning public companies, private equity–backed businesses, and early-stage ventures, he
has consistently driven innovation, operational scale, and commercial success.
Known
for his ability to lead international teams and navigate complex healthcare markets, Mr. Goodman is also a board member at Fourth Frontier,
a wearable health tech company.
A
retired U.S. Army officer, Mr. Goodman earned his degree from Norwich University and brings the discipline and strategic mindset developed
during his military career to his leadership in the private sector.
The
Company expects a seamless leadership transition with no disruption to operations, customer relationships, or strategic priorities.
About
Beyond Air, Inc.
Beyond
Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous
nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The
Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with
hypoxic respiratory failure. For more information, visit www.beyondair.net.
Forward-Looking
Statements
This
press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the leadership
transition, commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s
long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,”
“believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,”
“could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current
expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.
Because
forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the
Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These
risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial
strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively,
obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent
Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.
CONTACTS:
Investor
Relations contact
Corey
Davis, Ph.D.
LifeSci
Advisors, LLC
cdavis@lifesciadvisors.com
(212)
915-2577
GRAPHIC
GRAPHIC
Filename: ex99-1_001.jpg · Sequence: 4
Binary file (20043 bytes)
Download ex99-1_001.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Cover
Mar. 26, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Mar. 26, 2026
Entity File Number
001-38892
Entity Registrant Name
Beyond
Air, Inc.
Entity Central Index Key
0001641631
Entity Tax Identification Number
47-3812456
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
900
Stewart Avenue
Entity Address, Address Line Two
Suite 301
Entity Address, City or Town
Garden
City
Entity Address, State or Province
NY
Entity Address, Postal Zip Code
11530
City Area Code
(516)
Local Phone Number
665-8200
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common
Stock, par value $.0001 per share
Trading Symbol
XAIR
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration